Abu Dhabi: Abu Dhabi-backed health-care investment company M42 has taken a stake in biotech startup Juvenescence, a UK-based ...

M42 and Juvenescence will collaborate in drug discovery to develop a pipeline of innovative medicines to advance the ...

Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Pfizer has increased its dividend for 16 straight ... including migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven Pharmaceutical) and cancer drug Padcev (picked up ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

GSK resolves patent lawsuit against Pfizer over RSV vaccines British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial ...